Lack of Evidence for Deterioration in Endothelial Function Following Ticagrelor Treatment Cessation.

Lack of Evidence for Deterioration in Endothelial Function Following Ticagrelor Treatment Cessation. Curr Vasc Pharmacol. 2016 Jun 24; Authors: Xanthopoulou I, Vogiatzi C, Bampouri T, Chasapi A, Bei I, Davlouros P, Hahalis G, Alexopoulos D Abstract BACKGROUND: Ticagrelor may exert pleiotropic actions, beyond platelet inhibition, which are possibly adenosine-mediated. It has been suggested that in patients with coronary artery disease (CAD) ticagrelor may influence endothelial function. OBJECTIVE: We aimed to assess the possibility of endothelial function deterioration following ticagrelor treatment cessation. METHODS: This was a prospective, observational study, in stable CAD patients with prior percutaneous coronary intervention (PCI) for acute coronary syndrome manifested 1 year earlier, under ticagrelor maintenance dose (90 mg bid) and due to discontinue ticagrelor. Endothelial function was assessed by Peripheral Arterial Tonometry (EndoPat 2000 system, Itamar Medical, Caesarea, Israel) immediately after receiving the last tablet of ticagrelor (Day 0) and at Day 2 and Day 5 post-ticagrelor cessation. Reactive hyperaemia index (RHI) was calculated by automated software and endothelial dysfunction (ED) was defined as a RHI
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Vasc Pharmacol Source Type: research

Related Links:

I have never found it difficult to retrogradely cross a dangerous epicardial collateral in complex CTO. Delivering a twin stent in a partial culotte strategy for a bifurc lesion has never tested my talents. Stenting a left main across the LAD, jailing the LCX with OCT support is my favorite time pass. Crushing a calcium infested diffuse long lesion with diamond-tipped ablator appear as breezy as shopping in a mall. But this one is really challenging  What is that? Understanding these four studies (Ref 1-4 ). They dogmatically say medical management confers definitive protection in chronic coronary syndromes. It s...
Source: Dr.S.Venkatesan MD - Category: Cardiology Authors: Tags: acute coronary syndrome acc esc guidelines scai pci ptca stable chd courage bari 2d orbita ischemia trials tips and tricks in ptca Source Type: blogs
Confabulation of a confused cardiologist Yes, It has never bothered me to retrogradely cross a delicately dangerous epicardial collateral in complex CTO. Delivering a twin stent in a partial culotte strategy for a bifurc lesion has never tested my talents. Stenting a left main across the LAD, jailing the LCX with OCT support is my favorite time pass. Crushing a calcium infested diffuse long lesion with diamond-tipped ablator appear as breezy as shopping in a mall. Oh …I am terribly upset with this damn thing.  What is that? It requires 4 negative forces . . . to bring one big positive Impact! These studies say ...
Source: Dr.S.Venkatesan MD - Category: Cardiology Authors: Tags: acute coronary syndrome acc esc guidelines scai pci ptca stable chd courage bari 2d orbita ischemia trials tips and tricks in ptca Source Type: blogs
Publication date: February 2020Source: IJC Heart &Vasculature, Volume 26Author(s): Sahar Tariq, Rajesh Kumar, Madiha Fatima, Tahir Saghir, Sobia Masood, Musa KarimAbstractObjectivesTo assess the frequency of early (acute and sub-acute) stent thrombosis (ST) after primary percutaneous coronary intervention (pPCI) and to identify its potential predictors.BackgroundST is a serious clinical event associated with a high mortality rate. A very limited data are available regarding the incidence rate of early ST after pPCI and its predictors, especially for Pakistani population.MethodsStudy included consecutive patients who un...
Source: IJC Heart and Vasculature - Category: Cardiology Source Type: research
AbstractDiabetes mellitus (DM) is an independent predictor of adverse outcomes in patients with coronary artery disease (CAD). We investigated the interaction between DM and high platelet reactivity (HPR) in determining long-term clinical outcomes after percutaneous coronary intervention (PCI). We enrolled 500 patients who were divided based on the presence of DM and HPR. Primary endpoint was the occurrence of major adverse clinical events (MACE) at 5  years. Patients with both DM and HPR showed the highest estimates of MACE (37.9%, log-rankp 
Source: Journal of Cardiovascular Translational Research - Category: Cardiology Source Type: research
Coronary revascularization in patients with multi-vessel coronary artery disease (CAD) and diabetes has been an area of intense investigation. Diabetic patients currently comprise approximately 25% of all patients who undergo multi-vessel revascularization, either by percutaneous coronary intervention (PCI) or by coronary artery bypass grafting (CABG) surgery [1]. In comparison to non-diabetic patients, diabetes confers complex multi-vessel disease with more extensive and diffuse CAD [1,2]. Furthermore, diabetic patients experience worse outcomes than nondiabetic patients undergoing either CABG or PCI [1,2].
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research
ConclusionsTrimetazidine did not exert significant renal protective effect on preventing CIN and in hosptial  major adverse clinical events in unselected patients undergoing PCI.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
Diabetic patients with on-treatment high platelet reactivity (HPR) show an increased risk of thrombotic events. Whether measuring glycated haemoglobin (HbA1c) levels and/or glycaemic variability (GV) may help ...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Original investigation Source Type: research
Abstract BACKGROUND: Antithrombotic therapies that are optimal for atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI) have been studied but remain uncertain. We often encounter difficulties in choosing an appropriate antithrombotic therapy with antiplatelet agents after PCI in AF patients treated with oral anticoagulant due to a high CHADS2 score. Since there are no data on the incidences of PCI procedures in AF patients, we evaluated those incidences as well as the association between PCI and the CHADS2 score using data from the Fushimi AF Registry. METHODS: The Fushimi AF ...
Source: Journal of Cardiology - Category: Cardiology Authors: Tags: J Cardiol Source Type: research
Ticagrelor plus aspirin reduced ischemic events in patients with type 2 diabetes, stable coronary artery disease, and previous percutaneous coronary intervention (PCI), according to a trial published in The Lancet.
Source: JAMA - Category: General Medicine Source Type: research
Publication date: September 2019Source: Chinese Medical Sciences Journal, Volume 34, Issue 3Author(s): Qiang Chen, Liwei Zhang, Dangsheng Huang, Chunhong Zhang, Qiushuang Wang, Dong Shen, Minjun Xiong, Feifei YangObjectiveTo evaluate the instant effects and five-year clinical outcomes of coronary artery disease patients complicated with diabetes mellitus after StentBoost-optimized percutaneous coronary intervention (PCI).MethodsFrom March 2009 to July 2010, 184 patients undergoing PCI at our hospital were found stent underexpansion or malapposition by StentBoost after stents implantation and were divided into the diabetic ...
Source: Chinese Medical Sciences Journal - Category: General Medicine Source Type: research
More News: Angioplasty | Coronary Angioplasty | Diabetes | Drugs & Pharmacology | Endocrinology | Middle East Health | Percutaneous Coronary Intervention | Smokers | Study